Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT03875183
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Innolife Co., Ltd.
- Registry
-
NCT03875183 -
2019-000511-89
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, China
- Registry status
- Unknown status
Technical summary
Registry record NCT03875183. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-20 (actual); primary completion 2022-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
- Acronym
- TRACER-HF
- Condition
- Heart Failure
- Condition
- Reduced Ejection Fraction
- Intervention (Drug)
- INL1
- Intervention (Other)
- Placebo
- Lead sponsor
- Innolife Co., Ltd.
Record details
- Record id
cardio:ct-nct03875183- Content hash
7e813417b7682214d78d6e85b08e8be93aa548247a40534b2c041d38adefed67